Chinyere Mercellina Chukwuani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chinyere Mercellina Chukwuani has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Akindeji Olugboji
2 shared publicationsEmmanuel Ugbene
2 shared publicationsA. A. Raji
College of Medicine
1 shared publicationAkim Odebunmi
1 shared publicationAkin Sowunhmi
1 shared publicationAyoade M. J. Oduola
1 shared publication
Latest Publications
- 1 July 2006
- Published by Elsevier in Health Policy
- Vol. 77 (2) , 182-201
A baseline survey of the Primary Healthcare System in South Eastern Nigeria
- 1 July 2006
- Published by Elsevier in Health Policy
- Vol. 77 (2) , 182-201
A baseline survey of the Primary Healthcare System in South Eastern Nigeria
- 22 June 2006
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 28 (2) , 91-95
Improving Access to Essential Drugs for Rural Communities in Nigeria: the Bamako Initiative Re-Visited
One of the major indices of the performance of the primary healthcare delivery remains improved access to essential drugs. The Bamako Initiative (BI) was introduced by WHO/UNICEF in the late 1980’s to improve access to essential drugs for the most vulnerable in the society and thus improve the health outcomes. However, almost 20 years post-inception, the outcomes and/or impact of the BI on the health indices of many implementing African countries remains varied, with not so significant improvement in health status being registered in a majority of countries. A review of literature suggests that the poor outcomes may be attributable to issues more fundamental than just the absence of adequate funding. Although the current Nigeria Drug Policy (NDP) clearly enunciates and provides policy direction for the core objective of the Bamako Initiative (BI), which is “EQUITABLE ACESS TO ESSENTIAL DRUGS at the community level”, it appears the implementation guidelines may not have drawn on the NDP policy guidelines to provide an adequate framework/tools to ensure efficient realization of the core objectives of the BI. This paper appraises the implementation of the BI in Nigeria within the context of the NDP. It reviews the current status of the BI in the country and attempts to proffer solutions for improvement and/or functionality. The paper seeks:
- 22 June 2006
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 28 (2) , 91-95
Improving Access to Essential Drugs for Rural Communities in Nigeria: the Bamako Initiative Re-Visited
One of the major indices of the performance of the primary healthcare delivery remains improved access to essential drugs. The Bamako Initiative (BI) was introduced by WHO/UNICEF in the late 1980’s to improve access to essential drugs for the most vulnerable in the society and thus improve the health outcomes. However, almost 20 years post-inception, the outcomes and/or impact of the BI on the health indices of many implementing African countries remains varied, with not so significant improvement in health status being registered in a majority of countries. A review of literature suggests that the poor outcomes may be attributable to issues more fundamental than just the absence of adequate funding. Although the current Nigeria Drug Policy (NDP) clearly enunciates and provides policy direction for the core objective of the Bamako Initiative (BI), which is “EQUITABLE ACESS TO ESSENTIAL DRUGS at the community level”, it appears the implementation guidelines may not have drawn on the NDP policy guidelines to provide an adequate framework/tools to ensure efficient realization of the core objectives of the BI. This paper appraises the implementation of the BI in Nigeria within the context of the NDP. It reviews the current status of the BI in the country and attempts to proffer solutions for improvement and/or functionality. The paper seeks:
- Open Access
- 29 April 2004
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (5) , 601-605
Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy
Summary: Objective To examine the possibility of a different extent of chloroquine (CQ) metabolism in human pregnancy by determining blood level profiles of the drug and its major metabolite, desethylchloroquine (CQM).Methods Five women in the early third trimester of pregnancy and five non‐pregnant women received each a single 600 mg oral dose of CQ and blood samples were collected at pre‐determined intervals following drug administration. Plasma concentrations of CQ and CQM were analysed by an established HPLC method.Results The Cmax and AUC0‐‐48 h of CQM were significantly higher in the pregnant than the non‐pregnant group (P = 0.009). The ratio AUC(CQ)/AUC(CQM) ranged from 0.09 to 0.35 among pregnant women, and from 1.70 to 4.81 among non‐pregnant women.Conclusion Results from this preliminary study indicate an occurrence of induction of metabolism of CQ in the early third trimester of pregnancy. In view of toxicological importance of CQ metabolites, it is suggested that caution should be exercised in evaluation of higher dosage regimen of CQ in pregnant women.
- 29 April 2004
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (5) , 601-605
Open AccessEvidence for increased metabolism of chloroquine during the early third trimester of human pregnancy
Summary: Objective To examine the possibility of a different extent of chloroquine (CQ) metabolism in human pregnancy by determining blood level profiles of the drug and its major metabolite, desethylchloroquine (CQM).Methods Five women in the early third trimester of pregnancy and five non‐pregnant women received each a single 600 mg oral dose of CQ and blood samples were collected at pre‐determined intervals following drug administration. Plasma concentrations of CQ and CQM were analysed by an established HPLC method.Results The Cmax and AUC0‐‐48 h of CQM were significantly higher in the pregnant than the non‐pregnant group (P = 0.009). The ratio AUC(CQ)/AUC(CQM) ranged from 0.09 to 0.35 among pregnant women, and from 1.70 to 4.81 among non‐pregnant women.Conclusion Results from this preliminary study indicate an occurrence of induction of metabolism of CQ in the early third trimester of pregnancy. In view of toxicological importance of CQ metabolites, it is suggested that caution should be exercised in evaluation of higher dosage regimen of CQ in pregnant women.
- 1 January 2002
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 24 (5) , 188-195
Survey of drug use practices and antibiotic prescribing pattern at a general hospital in Nigeria
Objective:To describe the current drug use practices at the institution, and gather baseline data, which can serve as a basis for designing an appropriate intervention to improve the drug use...
- 1 January 2002
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 24 (5) , 188-195
Survey of drug use practices and antibiotic prescribing pattern at a general hospital in Nigeria
Objective:To describe the current drug use practices at the institution, and gather baseline data, which can serve as a basis for designing an appropriate intervention to improve the drug use...
- 1 January 2001
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 21 (8) , 537-544
Mefloquine versus Proguanil in Short-Term Malaria Chemoprophylaxis in Sickle Cell Anaemia
- 1 January 2001
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 21 (8) , 537-544
Mefloquine versus Proguanil in Short-Term Malaria Chemoprophylaxis in Sickle Cell Anaemia
- 1 January 2000
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 23 (8) , 968-972
Bioavailability of Ciprofloxacin and Fleroxacin. Results of a Preliminary Investigation in Healthy Adult Nigerian Male Volunteers.
The absolute bioavailability (BA) of ciprofloxacin and fleroxacin were evaluated in 19 adult Nigerian male volunteers. Subjects meeting the selection criteria were randomized to receive treatment either with fleroxacin (200 mg-i.v. and 200 mg oral dose) or ciprofloxacin (200 mg-i.v. and 250 mg oral dose). The i.v./oral or oral/i.v. switch was made after a one week washout period. Blood and urine samples were collected at pre-determined time intervals over a 72 h period for analysis of drug levels. Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin. Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively. The absolute BA following oral administration was found to be 0.79+/-0.47 for ciprofloxacin and 1.01+/-0.78 for fleroxacin. When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin. Only 38% with ciprofloxacin and 59% with fieroxacin, of the administered dose, was excreted unchanged following oral administration. More work, however, needs to be done on ciprofloxacin to support and/or confirm the above findings. Fleroxacin, on the one hand, exhibited a different trend from that observed in the literature with respect to Cmax and AUC where the values observed in this study were 3--4 fold lower than expected following identical doses, whilst on the other hand the observed BA profile in this study was consistent with literature trends.
- 1 January 2000
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 23 (8) , 968-972
Bioavailability of Ciprofloxacin and Fleroxacin. Results of a Preliminary Investigation in Healthy Adult Nigerian Male Volunteers.
The absolute bioavailability (BA) of ciprofloxacin and fleroxacin were evaluated in 19 adult Nigerian male volunteers. Subjects meeting the selection criteria were randomized to receive treatment either with fleroxacin (200 mg-i.v. and 200 mg oral dose) or ciprofloxacin (200 mg-i.v. and 250 mg oral dose). The i.v./oral or oral/i.v. switch was made after a one week washout period. Blood and urine samples were collected at pre-determined time intervals over a 72 h period for analysis of drug levels. Following intravenous administration the maximum serum concentration (Cmax) was 2.7+/-1.06mg/l for ciprofioxacin and 0.99+/-0.41 mg/l for fleroxacin; the area under the blood level curve (AUC) was 8.82+/-3.19 mg x h/l with ciprofloxacin and 8.52+/-3.83 mg x h/l with fleroxacin. Following oral administration the Cmax was 1.52+/-0.94 mg/l with ciprofloxacin and 0.57+/-0.08 mg/l with fleroxacin; the AUC was 9.87+/-4.10 and 7.55+/-1.42 mg x h/l, respectively. The absolute BA following oral administration was found to be 0.79+/-0.47 for ciprofloxacin and 1.01+/-0.78 for fleroxacin. When these BA results were corrected for renal clearance [Cl(r)] and elimination half-life (t1/2) the values were reduced to 0.37+/-0.17 and 0.31+/-0.18, respectively, for ciprofloxacin and 0.53+/-0.23 and 0.99+/-0.38, respectively, for fleroxacin. Only 38% with ciprofloxacin and 59% with fieroxacin, of the administered dose, was excreted unchanged following oral administration. More work, however, needs to be done on ciprofloxacin to support and/or confirm the above findings. Fleroxacin, on the one hand, exhibited a different trend from that observed in the literature with respect to Cmax and AUC where the values observed in this study were 3--4 fold lower than expected following identical doses, whilst on the other hand the observed BA profile in this study was consistent with literature trends.